Search

Zentalis Pharmaceuticals Inc

Slēgts

4.26 3.65

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.04

Max

4.3

Galvenie mērījumi

By Trading Economics

Ienākumi

-42M

-78M

EPS

-0.59

Darbinieki

106

EBITDA

-42M

-77M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+88.56% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-34M

297M

Iepriekšējā atvēršanas cena

0.61

Iepriekšējā slēgšanas cena

4.26

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. aug. 23:56 UTC

Zions Bancorporation shares are higher in after-market hours, continuing gains amid broader market dynamics influenced by recent U.S. Consumer Price Index data.

2026. g. 12. aug. 23:56 UTC

News

Allegro Microsystems shares rose in after-market trading following Benchmark's initiation of coverage with a Buy rating. The stock closed at $42.52.

2026. g. 12. aug. 23:56 UTC

JinkoSolar shares are higher in after-market trading, reflecting a modest uptick since Wednesday's close amid U.S. Consumer Price Index data release.

2026. g. 12. aug. 23:56 UTC

Yum Brands Inc. shares are higher in after-market trading, reflecting routine performance amid broader market dynamics following the release of U.S. Consumer Price Index data.

2026. g. 12. aug. 23:56 UTC

Griffon Corp shares are higher in after-market hours, supported by U.S. Consumer Price Index data easing concerns over Federal Reserve interest rate hikes.

2026. g. 12. aug. 23:56 UTC

Social Media
News

STAAR Surgical shares are lower in after-market hours following an EPS miss, despite reporting second-quarter net sales of $93.5 million, a 111% increase.

2026. g. 12. aug. 23:56 UTC

MasTec Inc shares are higher in after-market hours, recovering from an earlier dip. The movement aligns with broader market dynamics following U.S. CPI data.

2026. g. 12. aug. 23:56 UTC

Molina Healthcare Inc shares are higher in after-market hours, following the release of U.S. Consumer Price Index data that met expectations.

2026. g. 12. aug. 23:56 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average and within the upper range for the month.

2026. g. 12. aug. 23:56 UTC

ETF Constituents

Vanguard FTSE Emerging Markets ETF shows modest after-market gains, supported by Taiwan Semiconductor and Pinduoduo. The ETF is near its one-month range's upper end.

2026. g. 12. aug. 23:56 UTC

Ares Capital Corp shares are lower in after-market hours, continuing a three-session decline amid market volatility following U.S. Consumer Price Index data release.

2026. g. 12. aug. 23:56 UTC

DaVita Inc shares are lower in after-market trading following a session peak. The stock remains under pressure, trading below its 20-day moving average.

2026. g. 12. aug. 23:56 UTC

ETF Constituents
Correlated Moves

VanEck Gold Miners ETF declines in after-market trading, impacted by top holdings including Pan American Silver's drop and slight decreases in silver prices.

2026. g. 12. aug. 23:56 UTC

Chevron Corp shares gained during after-market hours following the release of U.S. Consumer Price Index data, which eased concerns about Federal Reserve interest rate hikes.

2026. g. 12. aug. 23:56 UTC

Social Media

Snowflake Inc. shares advanced in after-market trading, buoyed by U.S. CPI data and positive sentiment in tech sector discussions.

2026. g. 12. aug. 23:56 UTC

Bristol-Myers Squibb Co shares rose in after-market trading following U.S. Consumer Price Index data, easing concerns about aggressive Federal Reserve interest rate hikes.

2026. g. 12. aug. 23:56 UTC

Gogo Inc. shares are higher in after-market trading, following the release of U.S. Consumer Price Index data that met expectations and eased rate hike concerns.

2026. g. 12. aug. 23:56 UTC

Comcast shares declined in after-market trading, following the release of U.S. Consumer Price Index data. The stock remains above its 20-day moving average.

2026. g. 12. aug. 23:56 UTC

elf Beauty Inc. shares are lower in after-market trading, continuing a four-session decline. The stock remains above its 20-day moving average.

2026. g. 12. aug. 23:54 UTC

Ambarella Inc. shares remained roughly flat in after-market hours, with no specific news identified. The stock is positioned above its 20-day moving average.

2026. g. 12. aug. 23:52 UTC

UK House Price Balance Shows Slight Improvement at -0.3%, Indicating Ongoing Market Challenges Despite Optimism for Future Stabilization

2026. g. 12. aug. 23:52 UTC

RBA Holds Cash Rate at 4.35% Amid Inflation Concerns; Assistant Governor Kent's Upcoming Speech Sparks Market Speculation

2026. g. 12. aug. 23:52 UTC

Canada's housing starts data set for release on August 18, following June's decline and amid government initiatives to boost affordable home construction.

2026. g. 12. aug. 23:52 UTC

Australia's Consumer Confidence Report Set for August 18 Amidst Cautious Market Sentiment and Economic Volatility.

2026. g. 12. aug. 23:52 UTC

Australia's Consumer Confidence Index release on August 18, 2026, faces cautious market expectations amid mixed economic signals and ongoing geopolitical tensions.

2026. g. 12. aug. 23:52 UTC

Brazil's Industrial Entrepreneur Confidence Index Expected to Remain Low Amid Economic Uncertainty, Anticipating Continued Pessimism Ahead of August 13 Release.

2026. g. 12. aug. 23:52 UTC

Australia's Investment Lending Data Release on August 14 Expected to Impact Housing Market Insights Amid Cautious Sentiment.

2026. g. 12. aug. 23:52 UTC

Japan's Upcoming Export Data Release on August 19, 2026, Expected to Reflect Trends in High-Tech Products Amid Global Economic Uncertainties.

2026. g. 12. aug. 23:52 UTC

Japan's Upcoming Balance of Trade Data Expected to Show Continued Deficits Amid Rising Imports and Geopolitical Tensions

2026. g. 12. aug. 23:52 UTC

JD.Com Inc. shares are lower in after-hours trading, reversing from an early gain amid broader market trends influenced by recent inflation data.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

88.56% augšup

Prognoze 12 mēnešiem

Vidējais 7.75 USD  88.56%

Augstākais 11 USD

Zemākais 4 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

5

Pirkt

3

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat